| KAI Starts Secondary Hyperparathyroidism Drug Study - Renal Business Today |
|
|
Renal Business Today Results obtained in the study will be used to select the appropriate dosing regimen for further development of KAI-4169 for the chronic management of SHPT in ESRD patients. Previous Phase 1 data demonstrated that single IV doses of KAI-4169 were safe |